BSH 2024 | The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy, PhD, Imperial College London, London, UK, provides insight into the development of invariant natural killer T (iNKT)-CAR T-cells for the treatment of hematological malignancies, including multiple myeloma (MM), lymphoma, and leukemia. This approach harnesses the iNKT cell, a rare immune cell, and combines it with CARs to produce an off-the-shelf treatment for patients. Dr Ponnusamy discusses the engineering of these cells, which will soon be investigated in clinical trials. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
